Paper Details

  1. Home
  2. Paper Details

Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.

Author: BatemanEric D, BleeckerEugene R, BusseWilliam W, DavisAngela M, ForthRichard, HaumannBrett, JacquesLoretta, LötvallJan, WoodcockAshley

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fluticasone furoate (FF), a novel inhaled corticosteroid, demonstrated efficacy in treating patients with persistent moderate-to-severe asthma, with no dose-response relationship observed across the tested doses.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. OBJECTIVES: To determine the optim...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/thoraxjnl-2011-200308

データ提供：米国国立医学図書館（NLM）

Fluticasone Furoate for Asthma: A New Inhaled Corticosteroid

The field of asthma is like a desert landscape, with unpredictable shifts in the environment. This study investigates the efficacy of fluticasone furoate (FF), a new inhaled corticosteroid, in patients with asthma who are not adequately controlled with medium-dose inhaled corticosteroids. It's like discovering a new type of oasis in the desert, offering a fresh approach to managing a challenging condition.

The study found that FF was effective in improving lung function and reducing asthma symptoms compared to placebo. It also showed comparable efficacy to fluticasone propionate, another inhaled corticosteroid. This suggests that FF could be a valuable option for patients with asthma who are not responding well to other treatments.

Fluticasone Furoate: A Promising Option for Asthma Treatment

This research highlights the potential of fluticasone furoate (FF) as a new treatment option for asthma. It's like finding a hidden oasis in the desert, offering hope and relief for those seeking a better way to manage their condition. The study's findings suggest that FF could be a valuable addition to the asthma treatment arsenal.

Managing Asthma: A Search for Effective Treatments

This study underscores the ongoing search for effective treatments for asthma. It's like a continuous quest to find the most hospitable oases in the desert, offering relief from the harsh conditions. By investigating new medications like FF, researchers are working to improve the lives of those living with asthma, giving them the tools to manage their condition and live full and active lives.

Dr.Camel's Conclusion

Fluticasone furoate (FF) shows promising potential as a new treatment option for asthma. It's like finding a new path through the desert, leading to a more comfortable and sustainable journey. With further research, FF could become a valuable resource for asthma patients, providing them with more effective and well-tolerated treatment options.

Date :
  1. Date Completed 2012-02-02
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

21828231

DOI: Digital Object Identifier

10.1136/thoraxjnl-2011-200308

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.